UBS has upgraded AstraZeneca to ‘neutral’ from ‘sell’, but given it a short-term ‘sell’ rating and cut its price target to 1,900p from 2,150p amid concerns that competition from generic drug manufacturers will hit earnings.
It said full own label versions of Seroquel and Nexium in the US could reduce earnings by 28% and 14% respectively.
No comments:
Post a Comment